Brief: Valbiotis Announces Completion Of Recruitment For Phase II HEART Clinical Study Conducted With TOTUM•070

Valbiotis SA

06/09/2021 16:50

Sept 6 (Reuters) - VALBIOTIS SA  ALVAL.PA :
    * ANNOUNCES COMPLETION OF RECRUITMENT FOR PHASE II HEART
CLINICAL
STUDY CONDUCTED WITH TOTUM•070 IN HYPERCHOLESTEROLEMIA, A RISK
FACTOR FOR CARDIOVASCULAR DISEASE
    * HEART CLINICAL STUDY, RESULTS OF WHICH WILL BE AVAILABLE
IN Q2
OF 2022
    * HEART STUDY IS KEY STEP IN DEVELOPMENT OF TOTUM•070 AND IN
COMMERCIALIZATION STRATEGY ON NON-DRUG HYPERCHOLESTEROLEMIA
MARKET, ESTIMATED AT 1.2 BLN EUROS IN EUROPE AND USA

Source text for Eikon:  ID:nBw6Bxll5a 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))